COPHF CRESO PHARMA LTD

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.05    OTCQB
As of 01/26/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  
Index country:  Australia
Country of incorporation:  
IPO date:  07/03/2019
Outstanding shares:  1,226,370,447
Average volume:  8,513
Market cap:   $79,714,079
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   -5.30
PB ratio:   2.71
PS ratio:   21.98
Return on equity:   -110.27%
Net income %:   -415.13%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy